

Keyword Index

1H-NMR spectroscopy A031

A

actin B030
 activity-based network analysis PR018, B022
 adipogenesis PR015
 advanced RCC PR002, A016
 antiangiogenic therapy PR009, A036
 apoptosis A038
 ATF4 A023
 ATG14 B010
 AURKA B015
 autophagy B010

B

B7-H7 A011
 biomarker A001, A039
 biomolecular condensates A040
 Blastemal Wilms tumor B028
 bone metastatic A013
 breakpoint-confined chromothripsis PR011, B001

C

Cadherin-17 CDH17 PR020, B029
 cancer metabolism B002
 CAR NK cell therapy A019
 CAR-T PR002, A016
 CAR-T therapy PR020, B029
 casdatifan PR006, A034
 IA025, PR006, PR012, PR015,
 PR018, A013, A023, B006,
 B022, B027
 ccRCC B007
 ccRCC mouse GEMM B018
 ccRCC surfaceome A007
 CD200

CD44	B014
CD8+ T Cells	PR008, A012, A017
CDK4	A033
CDK4/6 inhibition	PR017, B026
CDK9 inhibitors	B028
cell cycle	A033
cell therapy	A014
ceramides	A030
cfRNA	A041
cGAS signaling	PR007, A032
chemokine	PR016, B034
chromatin modifiers	B015
chromophobe	IA021
chromophobe renal cell carcinoma	PR003, A022, B024, B032, B033
chromosome 3p loss	PR011, B001
clear cell formation	PR005, A008
clear cell renal cell carcinoma	PR004, A015, A027, A030
clonal hematopoiesis	PR014, B013
condensate	B023
conditional reprogramming	B005
CRISPR Cas9 and Cas12a	B016
CRISPR Screening	A026
CRISPR-Cas9	PR015
CRISPRi enhancer screening	B021
CTR9	B028

D

dark genome	PR001, A002
de-differentiation	PR013, B012
denosumab	A037

E

EAAT3	A029
early events	PR012, B006
endothelial cells	A007
enhancer gene regulation	B021
ENPP3	A010
EPAS1	A037

F
 ferritinophagy PR003, A022
 ferroptosis IA021, PR003, PR004, A022,
 A026, A027, A035, B032
 fragmentomic A039
 FSP1 B032
 fusion oncoproteins A040

G
 gene expression A034
 genetic dependency A024
 genetic evolution PR013, B012
 genetic screening B016
 genetic vulnerabilities A026
 glucose tracing A023
 glycolysis A023
 GPNMB B014

H
 H3K27ac A025
 HIF IA018, A035
 HIF1 B002
 HIF2 VHL Cre B007
 HIF-2A PR006, A037
 HIF-2A belzutifan RCC B004
 HIF-2A inhibitor A021
 HIF-2A targeted therapies PR010, B017
 HIFA transactivation domains PR010, B017
 HIF-independent A025
 human A003
 humoral hypercalcemia of malignancy
 (HHM) A037

I
 ICI PR002, A016
 IMC integration PR019, B031
 immune checkpoint A011
 immune checkpoint inhibitor A009
 immune checkpoint inhibitors PR008, A012, B035
 immune checkpoint therapy A007

immune effects	B020
immune evasion	A004
immune microenvironment	PR019, B031
immune regulation	PR016, B034
immune spatial landscape	B033
immune-checkpoint inhibitors	A013
immunotherapy	A003, A005, A006, A018
intratumoral heterogeneity	PR013, B012
ISCA2	A035

K

kidney cancer	A037, B002, B030
---------------	------------------

L

lenvatinib	A015
lenvatinib TKI clinic	B004
lesion distribution	B003
lipid metabolism	PR004, A027
lipid transfer	PR005, A008
liquid biopsy	A039, A041
lymph nodes	A017

M

macrophage	PR009, A036
macrophages	PR005, A008
metabolism	A024, A025, A028
metabolomics	A023, B002
metastasis	A005, A028
metastatic clear cell renal cell carcinoma and nivolumab plus ipilimumab	A020
microbiome	B037
mitochondria	A001, B024, B030
mitochondrial	A023
mitochondrial dysfunction	PR018, B022
mitotic fragility	B015
molecular chaperones	A033
mouse genetics	A004
mouse model	B002
MTORC1	B002
mTORC1 signaling	PR017, B026

multi-omics integration A031

N

NEK5 PR018, B022
neoantigen discovery PR001, A002
nephrectomy B019
neutrophils as drug delivery A014
new WHO classification B036
NF- κ B PR015
NK cell activation A011
non-clear cell renal cell carcinoma B036
Novel Model for ccRCC B020
NRF2 B002
nuclear speckles IA025

O

obesity A030
opioids A018
organoid A028

P

patient-derived cells B005
pembrolizumab A015
peritumoral tertiary lymphoid structures
(pTLS) and biomarkers A020
PIM kinases A038
PLXNA1 oncogene B021
preclinical xenograft efficacy B004
predictive model B008, B009
prevalence B036
prodrug A010
profilin PR016, B034
prognosis B008
PROTAC B027
PROTACs PR018, B022
proteomics B019
PTHrP A037
pulmonary metastasis B009
pVHL and HIF2 B018

R

radiomic–metabolomic correlation	A031
random survival forest predictive model	B003
RANKL	A037
renal cancer	A037
	PR008, PR016, A012, A019, A021, A029, A034, B008, B009, B034, B037
renal cell carcinoma (RCC)	B003
renal cell carcinoma bone metastasis	PR011, B001
renal cell carcinoma evolution	B016
renal medullary carcinoma	PR010, B017
RNA abundance regulators	

S

sarcomatoid	A004, A005
sarcomatoid transformation	B033
sarcomatoid/rhabdoid renal cell carcinoma	B035
scRNA-seq	A003
single cell RNA-seq	PR019, B031
single-cell	B025
single-cell RNA sequence	A009
SLC1A1	A029
somascan	B024
Somatic CRISPR AAV	B007
spatial single-cell transcriptomics	PR009, A036
spatial transcriptomics	B035
systemic immunity	B019

T

T cell engager	A010
T cell therapy	PR001, A002
T cells	A001
targeted protein degradation	PR018, B022
TBK1	B027
TCA cycle	A023
T-cell chemotaxis	PR016, B034
T-cell cytotoxicity	A021
telomere biology	PR014, B013
TERT promoter	PR014, B013
TFE3	B023

TGFB sensor	A019
therapeutic target	A024
therapeutic targets	B018
TKI resistance	PR007, A032
TMAO	B037
TRAIL	A038
transcription factor	PR015
transcriptomics	A023
translocation	B025
translocation renal cell carcinoma (RCC)	PR017, PR020, A040, B026, B029
tRCC	B014, B023
TRIM24	PR016, B034
TSC1	B002
tuberous sclerosis	IA021
tumor antigens	A017
tumor immune microenvironment	PR007, A032
tumor infiltrating lymphocytes (TILs)	A020
tumor microenvironment	A006, B025
tumor-associated neutrophils	A014
U	
urine	A041
urological cancer	B005
V	
VHL	IA018, B002, B010
VHL and Pbrm1	PR012, B006
VHL deficient cancer	B020
VHL mutations	B011
VHL synthetic lethal	PR018, B022
Z	
zolendronate	A037